breakthrough technology for the treatment of neurological diseases.
Curix is committed to developing solutions that improve the treatment for neurological diseases. Currently, many life-threatening and debilitating neurological diseases cannot be treated because the blood-brain barrier hinders the delivery of therapeutic agents to the brain. Our breakthrough technology can noninvasively modulate the blood-brain barrier, enabling treatments for brain tumors and neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
microbubble-enhanced focused ultrasound for blood-brain barrier modulation.
Focused ultrasound (FUS) is an early-stage, noninvasive therapeutic technology. It has the potential to transform the treatment of numerous medical conditions by using ultrasound energy focused to target tissue deep within the body at submillimeter resolution without harmful radiation. FUS in combination with microbubbles induces temporarily and reversible opening (modulation) of the blood-brain barrier (BBB) in targeted areas in the brain, facilitating local drug delivery.
Figure adapted from: Bae et al., 2024; doi: 10.7150/thno.94206
our drug delivery enabling platform.
Curix is developing a drug delivery platform consisting of a microbubble injector system. This system is specifically designed for the formation and controlled intravenous administration of monodisperse microbubbles. The platform enables noninvasive modulation of the BBB when used in conjunction with FUS. It facilitates the delivery of therapeutic agents to the brain.
NEWS
stay informed.
Important notice: This technology is currently under development and has not yet been issued a CE certificate in accordance with the EU Medical Device Regulation. It is also not approved by the U.S. Food and Drug Administration for clinical use.